These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
740 related articles for article (PubMed ID: 17237497)
1. Immunosuppressive and anti-angiogenic sphingosine 1-phosphate receptor-1 agonists induce ubiquitinylation and proteasomal degradation of the receptor. Oo ML; Thangada S; Wu MT; Liu CH; Macdonald TL; Lynch KR; Lin CY; Hla T J Biol Chem; 2007 Mar; 282(12):9082-9. PubMed ID: 17237497 [TBL] [Abstract][Full Text] [Related]
2. The immunosuppressant FTY720 inhibits tumor angiogenesis via the sphingosine 1-phosphate receptor 1. Schmid G; Guba M; Ischenko I; Papyan A; Joka M; Schrepfer S; Bruns CJ; Jauch KW; Heeschen C; Graeb C J Cell Biochem; 2007 May; 101(1):259-70. PubMed ID: 17203465 [TBL] [Abstract][Full Text] [Related]
3. FTY720 (fingolimod) in Multiple Sclerosis: therapeutic effects in the immune and the central nervous system. Brinkmann V Br J Pharmacol; 2009 Nov; 158(5):1173-82. PubMed ID: 19814729 [TBL] [Abstract][Full Text] [Related]
4. Functional characterization of sphingosine 1-phosphate receptor agonist in human endothelial cells. Butler J; Lana D; Round O; LaMontagne K Prostaglandins Other Lipid Mediat; 2004 Jan; 73(1-2):29-45. PubMed ID: 15165029 [TBL] [Abstract][Full Text] [Related]
20. FTY720, a new class of immunomodulator, inhibits lymphocyte egress from secondary lymphoid tissues and thymus by agonistic activity at sphingosine 1-phosphate receptors. Chiba K Pharmacol Ther; 2005 Dec; 108(3):308-19. PubMed ID: 15951022 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]